We are pioneering a new therapeutic approach to treat debilitating ear, nose and throat (ENT) diseases that impact the lives of millions of people.
Our first product candidate targets chronic rhinosinusitis (CRS), which affects about 27 million - 11% of adults - in the U.S., and has no approved pharmaceutical treaments.
Oct 10, 2019 Lyra Therapeutics Announces Dana Washburn, M.D., as Chief Medical Officer
Sep 17, 2019 Lyra Therapeutics Adds Vineeta Belanger, Ph.D., as Senior Vice President of Clinical Affairs
